NCT06777433Phase 2Active not recruiting

Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

Study sponsor: Radiopharm Theranostics, Ltd · RADX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-04-23Actual

Enrollment · participants30Estimated

Source updated2026-08-12Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-06 · 3 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Jan 2026~~

+ After

23 Apr 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Brain Metastases From Solid Tumors

Treatments or interventions studied

RAD101 (18F-FPIA)Drug

Primary outcomes · main study measures

Read the study measures

measure: Concordance between RAD101 PET/MRI and MRI with macrocyclic gadolinium; description: Number, size, and proportion of SRS/SRT-treated lesions identified by both RAD101 PET/MRI and MRI (with macrocyclic gadolinium); timeFrame: 1 Week; measure: Concordance between RAD101 PET/MRI and MRI with macrocyclic gadolinium; description: Number, size, and proportion of SRS/SRT-treated lesions identified by RAD101 PET/MRI and not identified by MRI (with macrocyclic gadolinium); timeFrame: 1 Week; measure: Concordance between RAD101 PET/MRI and MRI with macrocyclic gadolinium; description: Number, size, and proportion of SRS/SRT-treated lesions not identified by RAD101 PET/MRI and identified by MRI (with macrocyclic gadolinium); timeFrame: 1 Week

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history